Experiment 356849
Compounds isolated
Details
| Property | Value |
|---|---|
| Pharmacology | |
| Administration route | IV |
| Organism | Empty organism |
| Citation | GORDON,M: DEEKS,S: DE MARZO,C: GOODGAME,J: GURALNIK,M: LANG,W: MIMURA,T: PEARCE,D: KANEKO,Y:. (1997). CURDLAN SULFATE (CRDS) IN A 21-DAY INTRAVENOUS TOLERANCE STUDY IN HUMAN IMMUNODEFICIENCY VIRUS (HIV) AND CYTOMEGALOVIRUS (CMV) INFECTED PATIENTS: INDICATION OF ANTI-CMV ACTIVITY WITH LOW TOXICITY.. 28(1/2) |
| Amount utilized | |
| Compound isolated | |
| Disease | THE PRIMARY OBJECTIVE OF THIS PHASE I/II STUDY WAS TO ASSESS THE SAFETY, EFFICACY, TOLERANCE AND IMMUNOLOGIC ACTIVITY OF THREE DOSES OF CRDS ADMINISTERED FOR 30 MINUTES I.V. ONCE DAILY FOR 21 DAYS IN HIV INFECTED INDIVIDUALS WITH CD4 CELLS AT <500 CELLS/MM3. OTHER OBJECTIVES WERE (1) TO DETERMINE WHETHER THE DOSE RESPONSE RELATIONSHIP VARIES BETWEEN PATIENTS TAKING A RTI AT ENTRY AND THOSE WHO ARE NOT; (2) TO ASSESS THE EFFECT OF CRDS IN CYTOMEGALOVIRUS INFECTIONS WHEN PRESENT; (3) TO ASSESS THE EFFECT OF CRDS ON CD4 LYMPHOCYTE LEVELS; (4) TO ASSESS THE EFFECT OF CRDS ON HIV; (5) TO ASSESS THE EFFECT OF CRDS ON P24 ANTIGEN AND PLATELET LEVELS; AND (6) TO DETERMINE THE EFFECTS OF CRDS WITH AND WITHOUT A RTI PRESENT. |
| Dose amount | 200.0 MG |
| Number | 2 |
| Qualitative result | ACTIVE |
| Animal | HUMAN ADULT |
| Per unit | DAY |
| Dose expression | DOSE |
| Gender | GIVEN TO BOTH SEXES |